全文获取类型
收费全文 | 6885篇 |
免费 | 577篇 |
国内免费 | 84篇 |
专业分类
耳鼻咽喉 | 749篇 |
儿科学 | 55篇 |
妇产科学 | 18篇 |
基础医学 | 595篇 |
口腔科学 | 18篇 |
临床医学 | 3849篇 |
内科学 | 119篇 |
皮肤病学 | 6篇 |
神经病学 | 982篇 |
特种医学 | 96篇 |
外科学 | 72篇 |
综合类 | 287篇 |
预防医学 | 44篇 |
眼科学 | 62篇 |
药学 | 337篇 |
1篇 | |
中国医学 | 220篇 |
肿瘤学 | 36篇 |
出版年
2023年 | 157篇 |
2022年 | 127篇 |
2021年 | 236篇 |
2020年 | 306篇 |
2019年 | 227篇 |
2018年 | 199篇 |
2017年 | 219篇 |
2016年 | 212篇 |
2015年 | 224篇 |
2014年 | 278篇 |
2013年 | 355篇 |
2012年 | 248篇 |
2011年 | 264篇 |
2010年 | 209篇 |
2009年 | 315篇 |
2008年 | 334篇 |
2007年 | 316篇 |
2006年 | 343篇 |
2005年 | 293篇 |
2004年 | 244篇 |
2003年 | 232篇 |
2002年 | 227篇 |
2001年 | 194篇 |
2000年 | 168篇 |
1999年 | 162篇 |
1998年 | 146篇 |
1997年 | 134篇 |
1996年 | 141篇 |
1995年 | 115篇 |
1994年 | 111篇 |
1993年 | 98篇 |
1992年 | 96篇 |
1991年 | 90篇 |
1990年 | 60篇 |
1989年 | 39篇 |
1988年 | 46篇 |
1987年 | 43篇 |
1986年 | 46篇 |
1985年 | 47篇 |
1984年 | 34篇 |
1983年 | 18篇 |
1982年 | 39篇 |
1981年 | 32篇 |
1980年 | 24篇 |
1979年 | 16篇 |
1978年 | 15篇 |
1977年 | 19篇 |
1976年 | 11篇 |
1972年 | 6篇 |
1971年 | 6篇 |
排序方式: 共有7546条查询结果,搜索用时 15 毫秒
1.
目的 调查分析青少年偏头痛患者述情障碍的特点,探讨述情障碍与父母教养方式及焦虑抑郁等心理症状的关系,为改善青少年偏头痛患者临床症状、提高其生活质量、维护其身心健康提供理论依据。方法 筛选2017年10月—2019年2月在石家庄市人民医院确诊的110名青少年偏头痛患者为研究对象,采用一般资料调查表、多伦多述情障碍评定量表(TAS-20)、父母教养方式评价量表(EMBU)、视觉模拟量表(VAS)、汉密尔顿焦虑量表、汉密尔顿抑郁量表进行问卷调查及评估。结果 1)青少年偏头痛患者的述情障碍检出率为47.3%,述情障碍总分为(49.33±17.02)分。焦虑、抑郁症状的发生率分别为68.1%、47.3%。2)述情障碍组父母情感温暖因子得分(t=1.350、4.064)低于非述情障碍组,父母过分干涉(t=1.069、2.621)、拒绝否认(t=3.611、2.020)、过度保护因子得分(t=3.578、2.621)高于非述情障碍组,差异有统计学意义(P<0.05)。述情障碍组青少年对疼痛、焦虑、抑郁情绪的感知得分高于非述情障碍组,差异有统计学意义(t=3.640、3.801、5.318, P<0.05)。述情障碍总分及各维度与父母情感温暖呈显著负相关 (r=-0.607~-0.207,P<0.05);述情障碍总分及各维度与疼痛程度、焦虑水平、抑郁水平均呈显著正相关 (r=0.456~0.963,P<0.05)。3)述情障碍可以作为父母教养方式的中介变量对青少年偏头痛的疼痛及焦虑抑郁症状产生影响。结论 青少年偏头痛患者存在一定程度的述情障碍,父母教养方式对述情障碍有影响,并可以通过述情障碍的中介作用影响患者情绪状态及对疼痛的感知。 相似文献
2.
3.
《Saudi Pharmaceutical Journal》2022,30(8):1153-1158
BackgroundMigraine is one of the neurological diseases that have a negative impact on subjects’ productivity and daily activity of patients. Introducing monoclonal antibodies as a valuable option for resolving the persistent problem of migraine is still under investigation. The current study aimed to evaluate the efficacy and safety profile related to Erenumab.MethodsA prospective study for clinical data collection and analysis from recruited therapy-refractory migraine subjects were carried through 6 months for each subject. All subjects received Erenumab 70 mg monthly. Each patient provided the clinical data monthly starting from 0 months and for the next 6 months. Migraine disability assessment (MIDAS) questionnaire was used for evaluation of the Erenumab efficacy every 3 months. In addition, data regarding adverse effects, migraine triggers, and the impact of previous COVID-19 on migraine severity were collected and analyzed.ResultsNinety subjects were recruited in the study. Erenumab injections resulted in a significant (p < 0.001) reduction in MIDAS score in the 3rd month compared with baseline, also this significance was continuous in the 6th month. In contrast, there was no significant difference in the 6th month compared with the 3rd. Previously infected COVID-19 subjects showed a higher severity of migraine attacks compared with non-infected subjects. Skin redness and local pain were the most common adverse effects 63.3%, 47.77% respectively associated with Erenumab.ConclusionUsing Erenumab therapy showed a great beneficial impact regarding the reduction of migraine-related disabilities. COVID-19 was related to the increased severity of migraine attacks. 相似文献
4.
5.
《Gait & posture》2022
BackgroundVisually induced dizziness can develop as a sequala of a vestibular disorder and is characterized by symptoms of nausea, dizziness, and imbalance in rich visual environments such as supermarkets and shopping malls. To date the mechanisms underlying visually induced dizziness are poorly understood.Research questionWhat are the characteristics of visual fixations and postural sway in adults with visually induced dizziness compared to healthy adults when exposed to increasingly complex visual environments?MethodsWe recruited 20 adults with visually induced dizziness and 20 healthy adults to this cross-sectional exploratory study. Participants were instructed to maintain gaze on letters projected on a large screen with backgrounds of differing visual complexity. The number of visual refixations, movement of the centre of pressure, and movement of the head and body centres of mass were recorded.ResultsAdults with visually induced dizziness showed a significantly higher number of visual refixations (F= 10.592, p < 0.01), and increased mean velocity of head and body centres of mass movement (F= 14.034, p < 0.01 and F= 6.553, p < 0.05 respectively) compared to healthy adults.SignificanceAdults with visually induced dizziness exhibited visual fixational instability and increased postural and head sway compared to healthy adults. This was mainly observed in conditions with complex and moving backgrounds. This may account for reports from adults with visually induced dizziness of worsening symptoms in busy environments. The results from the study may assist in guiding intervention development to reduce symptoms of visually induced dizziness. 相似文献
6.
7.
目的 探讨天舒胶囊联合氟桂利嗪治疗前庭性偏头痛的临床效果.方法 选取2019年1月—2021年6月天津市第三中心医院分院中医科诊治的120例前庭性偏头痛患者,按随机数字表法分为对照组和治疗组,每组各60例.对照组患者口服盐酸氟桂利嗪胶囊,10 mg/次,1次/d.治疗组在对照组基础上口服天舒胶囊,4粒/次,3次/d.两组疗程均为12周,随访期为8周.观察两组的临床疗效,比较两组眩晕视觉模拟评分(VAS)、临床症状、眩晕障碍量表(DHI)和脑血流速度.结果 治疗后,治疗组明显改善率是73.3%,明显高于对照组的33.3%(P<0.05).治疗后,两组VAS评分均显著降低,眩晕平均每月发作次数与持续时间均显著减少(P<0.05);治疗后,治疗组VAS评分和临床症状改善均优于对照组(P<0.05).治疗后,两组躯体评分、情绪评分、功能评分及DHI总分均显著降低(P<0.05);治疗后,治疗组DHI评分显著低于对照组(P<0.05).治疗后,两组大脑椎动脉(VA)和基底动脉(BA)的平均血流速度均显著降低(P<0.05);治疗后,治疗组VA和BA的平均血流速度均低于对照组(P<0.05).结论 天舒胶囊联合氟桂利嗪治疗前庭性偏头痛疗效良好,可改善临床症状,缩减发作频率及发作时间,在躯体及情绪维度提升患者生活质量,值得临床推广. 相似文献
8.
9.
10.